缺血性中风后检测到心房颤动的病理生理学和风险 (PARADISE)
缺血性中风 (PARADISE) 后检测到的心房颤动的病理生理学和风险:前瞻性非干预队列研究
This prospective non-interventional cohort study investigates the pathophysiology of Atrial Fibrillation Detected After Stroke or transient ischemic attack (AFDAS) by comparing the autonomic function and inflammation between patients with AFDAS, patients with atrial fibrillation (AF) diagnosed before the ischemic event or known AF (KAF), and patients with normal sinus rhythm (NSR) after 14 day of cardiac monitoring following the event onset.
研究概览
地位
地位
详细说明
This study enrolls patients with acute ischemic stroke at the London Health Sciences Center in London, Ontario, Canada. The heart rhythm of the patients is monitored with a CardioSTAT® Holter device (Icentia) for 14 days after the ischemic event onset. Based on this cardiac monitoring and previous medical history, patients are stratified into three groups: (a) atrial fibrillation detected after stroke or transient ischemic attack (AFDAS), (b) atrial fibrillation diagnosed before the ischemic event or known AF (KAF), and (c) normal sinus rhythm (NSR).
Autonomic function is assessed by the levels of plasma catecholamines, a battery of validated autonomic tests [autonomic reflex screening (ARS)], heart rate variability (HRV) through data obtained by Holter monitoring by standard quantitative analysis methods according to the guidelines of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology and by the analysis of diurnal variation of heart rate. Blood samples are collected for the analysis of inflammatory markers (e.g. CRP, TNF-α, IL-1β, and IL-6), and potential AFDAS predictors such as brain natriuretic peptide (BNP- AFDAS biomarker), endothelin-1 (endothelial dysfunction marker), Lipoprotein(a) [Lp(a)] and thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels, TAFI activity, TAFI single nucleotide polymorphisms (SNPs), apo(a) isoform size and plasma catecholamines levels. Furthermore, specific neuroimaging findings (e.g., specific regions of the insula or its connections) and clinical features (e.g., impaired interoceptive processing, cognitive impairment, etc) are also analyzed. Interoception is assessed using a heartbeat detection task without feedback condition and gait, balance, frailty, and cognitive status in patients are evaluated by the administration of a battery of tests. Stroke recurrence will be assessed by a structured phone interview at 6 and 12 months after the initial stroke.
研究类型
研究类型
注册 (实际的)
注册
联系人和位置
学习地点
-
-
Ontario
-
London、Ontario、加拿大、N6A 5A5
- University Hospital, London Helath Sciences Center
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Ischemic stroke and transient ischemic attack patients presenting at the University Hospital of the London Health Science Center, London, Ontario, Canada.
描述
Inclusion Criteria:
- MCA territory-transient ischemic attack or -acute ischemic stroke patients seen in the Emergency Department or admitted to University Hospital, London, Ontario, Canada
- Age ≥ 18 years old
- Patient or Substitute Decision Maker must give written informed consent
Exclusion Criteria:
- Patients with autonomic dysfunction such as Parkinson's disease that can be interfering with outcome assessment based on qualified investigator's judgment.
- Patients taking tricyclic antidepressant (TCAs)
- Patients in whom the acute stroke is primarily hemorrhagic
- Patients with both TIA and atrial fibrillation
- Patients with both TIA and large vessel disease
- Patients with inflammatory diseases
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
团体/队列数
队列和干预
团体/队列团体/队列 |
|---|
|
AFDAS
patients without history of atrial fibrillation before the qualifying stroke or transient ischemic attack who are diagnosed with atrial fibrillation during the 14 days of monitoring |
|
KAF
atrial fibrillation known before the stroke or transient ischemic attack |
|
NSR
patients without a history of atrial fibrillation who do not develop atrial fibrillation during the 14 days of cardiac monitoring |
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Changes and Differences in Autonomic Function
大体时间:Within 48 hours of stroke onset and at 12, 30 and 90 days.
|
Differences in Composite Autonomic Severity Score (CASS) on an 11-point scale between patients with (a) AFDAS, (b) KAF , and (c) NSR |
Within 48 hours of stroke onset and at 12, 30 and 90 days.
|
|
Changes and Differences in Inflammatory Responses
大体时间:Within 48 hours of stroke onset and at 12, 30 and 90 days.
|
Differences in levels of plasma markers or temporal responses (CRP,TNFα, IL-6, IL-1β, etc) between patients with (a) AFDAS, (b)KAF and (c) NSR. |
Within 48 hours of stroke onset and at 12, 30 and 90 days.
|
|
Changes and Differences in Heart Rate Variability (HRV)
大体时间:At 14 days.
|
Differences in HRV parameters between patients with (a) AFDAS, and (b) NSR |
At 14 days.
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Biomarkers
大体时间:Within 48 hours of stroke onset, at 12, 30 and 90 days and at 6 months.
|
Differences in levels of plasma markers (BNP,endothelin-1, Lp(a), and TAFI) or neuroimaging/clinical predictors between patients with (a) AFDAS , (b) KAF and (c) NSR |
Within 48 hours of stroke onset, at 12, 30 and 90 days and at 6 months.
|
|
Atrial Fibrillation Burden
大体时间:At 14 days
|
Difference in atrial fibrillation burden (sum of atrial fibrillation episodes for a period of time) of AFDAS subjects with mild stroke/TIA compared to AFDAS subjects with moderate/severe stroke. |
At 14 days
|
|
Gait Impairments
大体时间:At 6 months
|
Differences in gait parameters in patients with a) AFDAS , (b) KAF and (c) NSR. |
At 6 months
|
|
Frailty
大体时间:At 6 months
|
Differences in frailty in patients with (a) AFDAS , (b) KAF and (c) NSR |
At 6 months
|
|
Cognitive Impairment
大体时间:At 6 months
|
Differences in cognition in patients with (a) AFDAS , (b) KAF and (c) NSR |
At 6 months
|
其他结果措施
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Stroke Recurrence
大体时间:At 90, 180, and 360 days
|
Number of stroke recurrences in patients with (a) AFDAS , (b) KAF and (c) NSR |
At 90, 180, and 360 days
|
|
Death
大体时间:At 90, 180, and 360 days
|
Number of deaths in (a) AFDAS , (b) KAF and (c) NSR groups |
At 90, 180, and 360 days
|
合作者和调查者
赞助
赞助
合作者
合作者
调查人员
调查人员
- 首席研究员:Luciano A Sposato, MD、Lawson Health Research Institute, London Health Sciences Center, Western University
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (实际的)
初级完成
研究完成 (实际的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- R-17-032
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.